The latest price target for Quoin Pharmaceuticals (NASDAQ:QNRX) was reported by Maxim Group on March 15, 2024. The analyst firm set a price target for $4.00 expecting QNRX to rise to within 12 months (a possible 540.41% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Quoin Pharmaceuticals (NASDAQ:QNRX) was provided by Maxim Group, and Quoin Pharmaceuticals maintained their buy rating.

There is no last upgrade for Quoin Pharmaceuticals

There is no last downgrade for Quoin Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quoin Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quoin Pharmaceuticals was filed on March 15, 2024 so you should expect the next rating to be made available sometime around March 15, 2025.

While ratings are subjective and will change, the latest Quoin Pharmaceuticals (QNRX) rating was a maintained with a price target of $15.00 to $4.00. The current price Quoin Pharmaceuticals (QNRX) is trading at is $0.62, which is out of the analyst’s predicted range.